首页/数据集/Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized study

Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized study

NCATS Open Data2022-06-17 更新2026-08-08 收录

新冠疫苗异源加强免疫

老年人群疫苗有效性研究

数据链接：

https://doi.org/10.1101/2022.06.03.22275983 数据链接链接失效反馈

官方服务：

资源简介：

Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized study

应用场景：

创建时间：

2022-06-06

新冠疫苗异源加强免疫

中和抗体评估

Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine

NCATS Open Data2022-12-16 更新20

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial

新冠疫苗异源加强免疫

疫苗免疫原性

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trial

NCATS Open Data2022-03-11 更新00

Safety and immunogenicity of heterologous booster immunization with Ad5-nCoV after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults: a randomized, double-blind, parallel-controlled trial

新冠疫苗异源加强免疫

免疫原性评估

Data on safety and immunity of heterologous booster (fourth dose) after three-dose priming with inactivated SARS-CoV-2 vaccine are limited in Chinese adults. Here, we evaluate the safety and immunogen

Zenodo2023-05-09 更新00

DataSheet_1_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.docx

新冠疫苗异源加强免疫

疫苗免疫原性

BackgroundEffective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in

NIAID Data Ecosystem10

新冠疫苗异源加强免疫

疫苗免疫原性临床评估

NIAID Data Ecosystem00